Healthcare M&A Finds Discipline. Digital Health Finds Momentum

Good morning, ! This week we're covering healthcare M&A’s discipline in the Americas, quarterly healthtech VC value segmented, digital health finding its foot again, and a operational & back-end competitive landscape snapshot. 

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here

— The Healthcare150 Team

THE 60-SECOND BRIEF

The week's pulse in private markets.

• Healthcare financing is back—but discipline is driving the market. Deal value is rebounding, yet lenders and sponsors remain focused on resilient cash flows, lower leverage, and higher-quality assets.

• Healthtech funding remains highly concentrated. Strip out a handful of mega-rounds, and venture investment continues to reflect one of the toughest fundraising environments since the post-pandemic reset.

• AI is attracting capital—but only with proven ROI. Investors are rewarding companies that improve clinical workflows, provider productivity, and revenue cycle performance—not those simply adding AI to their pitch.

• Quality now commands a premium. Whether raising debt, equity, or venture capital, businesses with durable fundamentals are widening the gap over the rest of the market.

• The next healthcare winners won't be those with the best story—they'll be those with the strongest execution.

DATA DIVE

Healthcare Financing Becomes a Competitive Advantage

Healthcare dealmaking is recovering, but capital is no longer the constraint. Access to quality capital is. Transaction value across the Americas is projected to reach $281B in 2026, up from $216B in 2025, yet still well below the $377B peak reached in 2021. The difference this cycle is not demand. It is financing discipline.

Private credit continues to fund acquisitions, but leverage has remained tightly anchored around 4.7x to 4.9x EBITDA, while sponsors are contributing roughly 59% of LBO financing. At the same time, strategic buyers are paying higher multiples than private equity, reflecting stronger balance sheets and a greater ability to underwrite synergies rather than financial engineering.

The implication is clear. Healthcare has entered a two-speed capital market. Businesses with predictable cash flow, resilient reimbursement, and strong margin profiles continue to attract competitive financing. Operators relying on aggressive EBITDA adjustments or highly leveraged capital structures face materially higher borrowing costs and narrower exit options. In 2026, financing quality is becoming as important as asset quality.

Read the Full Report HERE

HEALTHTECH CORNER

Big Rounds Can't Hide a Cooling Market

The headline from PitchBook's Q2 2026 Healthtech Report is impossible to ignore: Commure's $7 billion financing. But strip out that mega-round and a different picture emerges. Global healthtech VC funding totaled just $2.7 billion in Q2, down 39.9% YoY and 51.8% sequentially, making it one of the weakest quarters since the post-pandemic correction.

The chart tells the story. After the funding frenzy of 2021, quarterly deal value settled into a much lower range through 2023-2025. Q1 2026 appeared to signal a recovery, but Q2 reminds investors that capital remains highly selective. Rather than broad-based enthusiasm, today's market is rewarding a handful of category leaders while leaving the rest of the ecosystem in a much tougher fundraising environment.

Why it matters: Healthtech isn't short on capital—it is short on distributed capital. Investors continue to back companies with proven scale, AI infrastructure, or strategic relevance, but early- and growth-stage startups are competing in an increasingly concentrated funding market. For founders, the message is clear: execution matters more than vision. For investors, this environment is likely to produce attractive entry valuations, but only for businesses that can demonstrate durable fundamentals rather than growth at any cost.

Read more

PRESENTED BY CAPLINK X PE 150

You’re invited: Where AI Meets Private Equity

Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.

On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.

The morning will feature three practitioner-led discussions:

• AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies. Sponsored by Exact Insight.

• AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management.

• Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.

Interested in attending? Register or request the full agenda here.

Interested in sponsoring? Email [email protected] 

COMPETITIVE LANDSCAPE SNAPSHOT

TREND TO WATCH

AI Is Reopening the Healthtech Funding Window

After three years of capital discipline, digital health is finding its footing again—but this isn't a broad market recovery. It's an AI story.

Digital health startups attracted $4 billion in Q1 2026, up from $3 billion a year earlier, with 59% of all funding concentrated in just 12 mega-rounds. Average deal sizes climbed to their highest level since 2021, underscoring that investors are writing bigger checks—but to fewer companies.

The winners share a common theme: AI solutions embedded into clinical workflows, provider productivity, revenue cycle management, and decision support. Investors are increasingly rewarding businesses that can demonstrate measurable ROI rather than simply layering generative AI onto existing products. At the same time, M&A activity and a slowly reopening IPO market are giving investors greater confidence that exit opportunities are returning.

Why it matters: Healthtech funding is no longer recovering because digital health is back—it is recovering because AI is proving commercially viable. Capital remains selective, but companies that solve tangible operational problems with defensible AI capabilities are once again commanding premium valuations. For investors, the next cycle won't be defined by who has AI, but by who can monetize it.

Read more

INTERESTING ARTICLES